Combination of citalopram and nortriptyline in the treatment of severe major depression: A double-blind, placebo-controlled trial

Therapy

Volumn 4, Issue 2, 2007, Pages 187-192

  Raisi, Firoozeh ^a   Habibi, Nastaran ^a   Nasehi, Abbas Ali ^b   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Iran Helal Institute of Applied Science and Technology   (Iran)

Author keywords

Citalopram; Major depression; Nortriptyline; Polypharmacy

Indexed keywords

CITALOPRAM; FLUOXETINE; NORTRIPTYLINE; PLACEBO;

ADULT; ANAMNESIS; ANOREXIA; ANORGASMIA; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; IMPOTENCE; INSOMNIA; LIBIDO; MAJOR DEPRESSION; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SWEATING; TACHYCARDIA; TREATMENT DURATION; TREMOR; URINE RETENTION; VISUAL DISORDER; VOMITING; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

EID: 33947630716     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.2.187     Document Type: Article

References (31)

1. Judd L: Mood disorders in the general population represent an important and worldwide public health problem. Int. J. Clin. Psychopharmacol. 10(Suppl. 4), 5-10 (1995).
2. MacDonald TM: Treatment of depression: prescription for success? Prim. Care Psychiatry 3 (Suppl. 1), 7-10 (1997).
3. World Health Organization: The introduction of a mental health component into primary health care. World Health Organization, Geneva, Switzerland (1990).
4. Macher JP: Noradrenergic dysfunction and antidepressant treatment response. Eur. Neuropsychopharmacol. 11, 163-168 (2001).
5. Andrews JM, Ninan PT, Nemeroff CB: Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 4, 48-56 (1996).
6. Eriksson E: Antidepresant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin? Acta Psychiatrica Scanddinovica 402, 12-17 (2000).
7. Scates AC, Doraiswamy PM: Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann. Pharmacother. 34, 1302-1312 (2000).
8. Schatzberg AF: Clinical efficacy of reboxetine in major depression. J. Clin. Psychiatry 61, 31-38 (2000).
9. Shelton RC: The use of antidepressants in novel combination therapies. J. Clin. Psychiatry 64, 14-18 (2003).
10. Marangell LB: Augmentation of standard depression therapy. Clin. Ther. 22, 25-38 (2000).
11. Dording CM: Antidepressant augmentation and combination. Psychiatr. Clin. North Am. 23, 743-755 (2000).
12. Shelton CI: Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? J. Clin. Psychiatry 65, 29-33 (2004).
13. Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234-241 (2001).
14. Entsuah AR, Huang H, Thase ME: Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotimin reuptake inhibitors, or placebo. J. Clin. Psychiatry 62, 869-877 (2001).
15. Stahl SM, Entsuah R, Rudolph RL: Comparative efficacy between venlafaxine and SSRls: a pooled analysis of patients with depression.Biol. Psychiatry 52, 1166-1174 (2002).
16. Rudolph RL: Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinivca 415, 24-30 (2002).
17. Rodolph RL, Feiger AD: A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J. Affect. Disord. 56, 171-181 (1999).
18. Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and ventafaxine extended release in the treatment of major depressive disorder. J. Clin. Psychiatry 65, 1190-1196 (2004).
19. Zajecka JM, Albano D: SNRIs in the management of acute major depressive disorder. J. Clin. Psychiatry 65, 11-18 (2004).
20. Nelson JC: Augmentation strategies with seotonergic-noradrenergic combinations. J. Clin. Psychiatry 59, 65-68 (1998).
21. Taylor D: Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Br. J. Psychiatry 167, 557-580 (1995).
22. Fava M: Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiatry 62(Suppl. 18), 4-11 (2001).
23. Lam RW, Wan DD, Cohen NL, Kennedy SH: Combining antidepressants for treatment-resistant depression: a review. J. Clin. Psychiatry 63, 685-693 (2002).
24. Sonawalla SB, Fava M: Severe depression: is there a best approach? CNS Drugs 15, 765-776 (2001).
25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Forth edition (DSM-IV). American Psychiatric Association, Washington DC, USA (1994).
26. Hamilton M: A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 62-66 (1960).
27. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K: Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J. Clin. Psychiatry 50, 447-449 (1989).
28. Zajecka JM, Jeffries H, Fawcett J: The efficacy of fluoxetine combined with a heterocycilc antidepressant in treatment - resistant depression: a retrospective analysis. J. Clin. Psychiatry 56, 338-343 (1995).
29. Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH: Combining norepinephrine and serotonin reuptake inhibition for treatment of depression: a double-blind, randomized study. Biol. Psychiatry 55, 296-300 (2004).
30. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K: Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br. J. Psychiatry 161, 562-565 (1992).
31. Nelson JC, Mazure CM, Bowers MB, Jatlow PI: A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry 48, 303-307 (1991).